News

August 18, 2020August 18, 2020

Large-scale Testing of BRCA Mutations Can Be Cost-Effective, Study Finds

News

Screening the overall population for mutations in the genes BRCA1 and BRCA2 that can cause breast and ovarian cancer is cost-effective in wealthier countries, from the viewpoint of both payers and society, an ... Read more

August 13, 2020August 13, 2020

XMT-1536 on FDA Fast Track for Platinum-resistant, Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has given fast track designation to Mersana Therapeutics’ XMT-1536 as a possible treatment for women with platinum-resistant high-grade serous ovarian cancer who received up to three prior lines ... Read more

August 11, 2020August 11, 2020

Partnership Improves Patient Access to Apealea Outside US

News

Elevar Therapeutics and Tanner Pharma Group have partnered to make Apealea (paclitaxel micellar) accessible in areas outside the U.S. where the medication is not available. The companies have created a ... Read more

August 4, 2020August 4, 2020

Study: Tests Used to Predict Response to PARP Inhibitors Yield Inconsistent Result

News

Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability to repair their DNA — a status termed “homologous recombination deficiency” (HRD), and likely would ... Read more

July 30, 2020July 30, 2020

Liposomal Doxorubicin-based Regimen Improves Outcomes in Platinum-sensitive Ovarian Cancer

News

Second-line treatment with a combination of bevacizumab plus the chemotherapies carboplatin and pegylated liposomal doxorubicin may significantly improve the outcomes of platinum-sensitive ovarian cancer patients, compared to standard treatment, findings ... Read more

July 28, 2020July 28, 2020

Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer

News

China’s regulatory agency has granted priority review status to BeiGene‘s new drug application (NDA) requesting the approval of pamiparib, its investigational PARP inhibitor, for the treatment of advanced ovarian cancers. Priority review is ... Read more

July 23, 2020July 23, 2020

PARP Inhibitor Pamiparib Under Review in China to Treat Advanced Ovarian Cancer

News

China’s regulatory agency has agreed to consider a request that pamiparib, BeiGene‘s investigational PARP inhibitor, be approved to treat people with advanced ovarian cancers after at least two prior lines of chemotherapy. ... Read more

July 21, 2020July 21, 2020

Small Inhibitor May Boost Effectiveness of PARP Inhibitors in Some Ovarian Cancers, Mouse Study Finds

News

A small inhibitor that prevents cells from making ribosomes — the machinery used to produce proteins — may improve the effectiveness of PARP inhibitors in ovarian cancers with mutations in DNA repair ... Read more

July 16, 2020July 16, 2020

Tecentriq Combo Produces Disappointing Results in Advanced Ovarian Cancer Trial

News

The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not significantly extend survival without disease worsening in people with newly-diagnosed advanced ovarian cancer, a recent ... Read more

July 14, 2020July 14, 2020

$2.2M Awarded to Collaboration Researching Rare Form of Ovarian Cancer

News

A research collaboration led by the Hudson Institute of Medical Research as been awarded a $2.2-million grant to advance knowledge about ovarian granulosa cell tumors (GCT) and ultimately improve the ... Read more